55 related articles for article (PubMed ID: 3259531)
21. Spontaneous remission in Cushing's disease.
Dickstein G; Spindel A; Shechner C; Adawi F; Gutman H
Arch Intern Med; 1991 Jan; 151(1):185-9. PubMed ID: 1985595
[TBL] [Abstract][Full Text] [Related]
22. Plasma calcitonin response to a calcium clamp in endogenous Cushing's syndrome.
Tørring O; Bucht E; Thorén M; Sjöberg HE
Acta Endocrinol (Copenh); 1986 Feb; 111(2):258-63. PubMed ID: 3953235
[TBL] [Abstract][Full Text] [Related]
23. The effect of low-dose naloxone infusion on plasma ACTH and LH in patients with Cushing's and Addison's diseases.
Moreira AC; Foss MC; Iazigi N; Verissimo JM
Horm Metab Res; 1988 Apr; 20(4):230-4. PubMed ID: 2840381
[TBL] [Abstract][Full Text] [Related]
24. Osteocalcin in normal adult humans of different sex and age.
Galli M; Caniggia M
Horm Metab Res; 1985 Mar; 17(3):165-6. PubMed ID: 3873386
[No Abstract] [Full Text] [Related]
25. [Osteocalcin: an index of development of acromegaly?].
Oberlin F; Guillemant J; Guillemant S; Loison S; Turpin G
Presse Med; 1988 Feb; 17(4):166. PubMed ID: 2894670
[No Abstract] [Full Text] [Related]
26. Osteocalcin levels in osteogenesis imperfecta.
Rico H
J Pediatr; 1987 Oct; 111(4):634. PubMed ID: 3498810
[No Abstract] [Full Text] [Related]
27. Levels of osteocalcin in normal pregnancy.
Martinez ME; de Pedro C; Catalan P; Salinas M; Balaguer G; Ordas J
Am J Obstet Gynecol; 1985 Nov; 153(6):708-9. PubMed ID: 3877465
[No Abstract] [Full Text] [Related]
28. Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.
Szappanos A; Toke J; Lippai D; Patócs A; Igaz P; Szücs N; Füto L; Gláz E; Rácz K; Tóth M
Osteoporos Int; 2010 Apr; 21(4):637-45. PubMed ID: 19513576
[TBL] [Abstract][Full Text] [Related]
29. Skeletal involvement in adult patients with endogenous hypercortisolism.
Chiodini I; Torlontano M; Carnevale V; Trischitta V; Scillitani A
J Endocrinol Invest; 2008 Mar; 31(3):267-76. PubMed ID: 18401211
[TBL] [Abstract][Full Text] [Related]
30. Effect of single doses of dexamethasone and adrenocorticotrop hormone on serum bone markers in healthy subjects and in patients with adrenal incidentalomas and Cushing's syndrome.
Majnik J; Szücs N; Patócs A; Tóth M; Balogh K; Varga I; Gláz E; Rácz K
J Endocrinol Invest; 2004 Sep; 27(8):747-53. PubMed ID: 15636428
[TBL] [Abstract][Full Text] [Related]
31. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome.
Minetto M; Reimondo G; Osella G; Ventura M; Angeli A; Terzolo M
Osteoporos Int; 2004 Nov; 15(11):855-61. PubMed ID: 15034643
[TBL] [Abstract][Full Text] [Related]
32. The clinical evaluation of silent adrenal masses.
Ambrosi B; Passini E; Re T; Barbetta L
J Endocrinol Invest; 1997 Feb; 20(2):90-107. PubMed ID: 9125490
[No Abstract] [Full Text] [Related]
33. Serum bone Gla protein and carboxyterminal cross-linked telopeptide of type I collagen in patients with Cushing's syndrome.
Sartorio A; Conti A; Ferrario S; Passini E; Re T; Ambrosi B
Postgrad Med J; 1996 Jul; 72(849):419-22. PubMed ID: 8935602
[TBL] [Abstract][Full Text] [Related]
34. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.
Conti A; Sartorio A; Ferrero S; Ferrario S; Ambrosi B
J Endocrinol Invest; 1996 Feb; 19(2):127-30. PubMed ID: 8778165
[TBL] [Abstract][Full Text] [Related]
35. Osteocalcin levels in patients with microprolactinoma before and during medical treatment.
Sartorio A; Conti A; Ambrosi B; Muratori M; Morabito F; Faglia G
J Endocrinol Invest; 1990 May; 13(5):419-22. PubMed ID: 1974270
[TBL] [Abstract][Full Text] [Related]
36. Plasma osteocalcin values and related hormonal parameters in patients subjected to a variety of prostate anticancer agents.
Tarle M
Urol Res; 1991; 19(1):39-44. PubMed ID: 1851347
[TBL] [Abstract][Full Text] [Related]
37. Osteocalcin levels in Cushing's disease before and after treatment.
Sartorio A; Ambrosi B; Colombo P; Morabito F; Faglia G
Horm Metab Res; 1988 Jan; 20(1):70. PubMed ID: 3259531
[No Abstract] [Full Text] [Related]
38. [Basal serum osteocalcin in diseases associated with changes in bone metabolism].
León M; Larrodera L; Solís JA; Hawkins F
Med Clin (Barc); 1987 Jan; 88(3):90-2. PubMed ID: 3493401
[No Abstract] [Full Text] [Related]
39. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
40. [Studies of the basal secretion and the response to TRH (thyrotropin-relapsing factor) of TSH (thyrotropin) and prolactin in Cushing's syndrome and Nelson's syndrome (author's transl)].
Luton JP; Molinie P; Strauch G; Guilhaume B; Bricaire H
Sem Hop; 1981 May 8-15; 57(17-18):841-9. PubMed ID: 6262921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
